Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda

cafead

Administrator
Staff member
  • cafead   Jan 11, 2024 at 08:53: PM
via With sales declining for aging multiple sclerosis (MS) drug Fampyra, Biogen has exercised an option to return licensing rights outside of the United States to Acorda Therapeutics.

article source